E
Lexaria Bioscience Corp. LEXX
$0.62 $0.000.36% NASDAQ
Recommendation
Dividend Power Score
Prev Close
$0.62
Volume
115,811
Avg Vol (90D)
513,912
Market Cap
$15.44M
Dividend & Yield
--
52-Week Range
$0.46 - $1.90
P/E (TTM)
--
EPS (TTM)
-$0.57
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
Lexaria's Oral Liraglutide Shows Comparable Performance and Fewer Side Effects in Human Study
2/5/2026 - TipRanks Financial Blog
Lexaria Announces Positive Final Results From Human Pilot Study #5
2/5/2026 - ACCESS Newswire
Short Interest in Lexaria Bioscience Corp. (NASDAQ:LEXX) Decreases By 33.8%
1/31/2026 - Ticker Report
Lexaria Bioscience Shareholders Endorse Directors and Auditors
1/28/2026 - TipRanks Financial Blog
Lexaria Adds Six Global Patents, Reaches 60 Granted as It Rallies Shareholders Ahead of 2026 Meeting
1/22/2026 - TipRanks Financial Blog
Lexaria Bioscience awarded six additional patents
1/22/2026 - The Fly
Lexaria Awarded Six Additional Patents
1/22/2026 - ACCESS Newswire
THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point
1/21/2026 - Globe Newswire
Lexaria Bioscience (NASDAQ:LEXX) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS
1/15/2026 - Ticker Report
Lexaria Deepens GLP-1 Focus With DehydraTECH Advances, Patents and Fresh Capital
1/12/2026 - TipRanks Financial Blog
Lexaria Bioscience (LEXX) Advances Oral Drug Delivery with DehydraTECH
1/12/2026 - GuruFocus
Lexaria Releases Annual Letter from the CEO
1/12/2026 - ACCESS Newswire
Lexaria's Phase 1b GLP-1 Study Shows Comparable Metabolic Outcomes and Encouraging Blood Pressure Data for DehydraTECH Platform
12/30/2025 - TipRanks Financial Blog
Lexaria Bioscience (LEXX) Reports Promising Results from Phase 1b Study
12/30/2025 - GuruFocus
Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4
12/30/2025 - ACCESS Newswire
Lexaria Bioscience files to sell 2.75M shares of common stock for holders
12/29/2025 - The Fly
Lexaria Bioscience price target lowered by $2.50 at H.C. Wainwright, here's why
12/26/2025 - The Fly
Lexaria's DehydraTECH-Semaglutide Cuts GLP-1 Side Effects in Phase 1b Trial and Extends Cash Runway Into 2026
12/23/2025 - TipRanks Financial Blog
Lexaria Bioscience achieves primary endpoint in Phase 1b study GLP-1-H24-4
12/23/2025 - The Fly
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4
12/23/2025 - ACCESS Newswire
Lexaria Bioscience Corp. Announces Closing of $3. ...
12/16/2025 - GuruFocus
Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
12/16/2025 - ACCESS Newswire
Lexaria Bioscience Secures $3.5 Million in Direct Offering to Boost R&D
12/15/2025 - TipRanks Financial Blog
Lexaria Bioscience plummets on $3.5M equity offering
12/15/2025 - SeekingAlpha.com: All News
Lexaria Bioscience plummets on $3.5M equity offering
12/15/2025 - Seeking Alpha - Healthcare
Income Statement
Total Revenue (TTM)
$522.00K
EBITDA (TTM)
-$10.48M
EBIT (TTM)
-$10.55M
Net Income (TTM)
-$10.79M
Balance Sheet
Total Assets (Q)
$6.05M
Total Debt (Q)
$101.90K
Total Liabilities (Q)
$1.53M
Book Value Per Share (Q)
$0.221
Cash Flow
Cash from Operations (TTM)
-$8.71M
Cash from Investing (TTM)
-$210.30K
Cash from Financing (TTM)
$5.17M
Net Change in Cash (TTM)
-$3.80M
Filings
Filing Date
Tuesday, January 13, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of Apr 13 and 17 (est)
Price History
Loading...
Beta
0.62
7-Day Total Return
-14.11%
30-Day Total Return
0.89%
60-Day Total Return
-38.37%
90-Day Total Return
-25.89%
Year to Date Total Return
-4.82%
1-Year Total Return
-59.31%
2-Year Total Return
-74.70%
3-Year Total Return
-77.20%
5-Year Total Return
-91.37%
52-week Low
Dec 26, 2025 - $0.46
52-week High
Mar 24, 2025 - $1.90
Valuation
Market Cap
$15.44M - Nano Cap
Enterprise Value
$10.73M
Price/Sales (TTM)
25.42
Price/Book (Q)
2.81
Dividends and Shares
Shares Outstanding
21.38M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
lexariabioscience.com
Phone Number
250 765 6424
Address
740 McCurdy Road
Kelowna, BC V1X 2P7
Country
Canada
Year Founded
2004
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical... more
NASDAQ 02/13/2026 4:00PM Eastern Quotes delayed